知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

1012 条记录 (耗时 0.043 秒)

    Tuberculosis antigen detection assays and vaccines
    62.
    发明授权
    Tuberculosis antigen detection assays and vaccines 有权
    结核病抗原检测试验和疫苗

    公开(公告)号：US07968694B2

    公开(公告)日：2011-06-28

    申请号：US11478366

    申请日：2006-06-29

    申请人： Antonio Campos-Neto ,  Suely S. Kashino

    发明人： Antonio Campos-Neto ,  Suely S. Kashino

    IPC分类号： C07H21/04 ,  C07H21/02 ,  A61K39/04

    CPC分类号： G01N33/5695 ,  A61K39/00 ,  A61K2039/53 ,  C07K14/35 ,  C07K2319/00 ,  C12Q1/6883 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N2800/12

    摘要： The present invention relates to isolated Tuberculosis (TB) antigens that are useful in therapeutic and vaccine compositions for stimulating a TB specific immunological response. The identified antigens are also useful in diagnostic assays to determine the presence of active TB in an individual. Accordingly, the present invention includes polypeptide molecules, nucleic acid molecules, vaccine compositions, diagnostic assays, and methods of diagnosis and monitoring treatment related to these TB antigens.

    摘要翻译： 本发明涉及可用于刺激TB特异性免疫应答的治疗剂和疫苗组合物中的分离的结核病（TB）抗原。 所鉴定的抗原也可用于诊断测定以确定个体中活性TB的存在。 因此，本发明包括多肽分子，核酸分子，疫苗组合物，诊断测定以及与这些TB抗原相关的诊断和监测治疗方法。

    Lentiviral vectors for the preparation of immunotherapeutical compositions
    63.
    发明授权
    Lentiviral vectors for the preparation of immunotherapeutical compositions 有权
    用于制备免疫治疗组合物的慢病毒载体

    公开(公告)号：US07968332B2

    公开(公告)日：2011-06-28

    申请号：US10313038

    申请日：2002-12-06

    申请人： Pierre Charneau ,  Hüseyin Firat ,  Véronique Zennou

    发明人： Pierre Charneau ,  Hüseyin Firat ,  Véronique Zennou

    IPC分类号： C12N15/00 ,  A61K39/12 ,  C12Q1/70

    CPC分类号： C12N15/867 ,  A61K48/00 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/57 ,  C07K14/35 ,  C12N15/86 ,  C12N2740/16043 ,  C12N2740/16134 ,  C12N2830/48 ,  C12N2830/50 ,  C12N2840/203

    摘要： The invention relates to an immunogenic composition comprising a recombinant vector characterized in that it comprises a polynucleotide comprising the cis-acting central initiation region (cPPT) and the cis-acting termination region (CTS), these regions being of retroviral or retroviral-like origin, said vector comprising in addition a defined nucleotide sequence (transgene or sequence of interest) and regulatory signals of retrotranscription, expression and encapsidation of retroviral or retroviral-like origin, wherein the composition is capable of inducing or of stimulating a cell-mediated response for instance a CTL (Cytotoxic T Lymphocytes) response or a CD4 response, against one or several epitopes encoded by the transgene sequence present in the vector.

    摘要翻译： 本发明涉及包含重组载体的免疫原性组合物，其特征在于其包含包含顺式作用中枢起始区（cPPT）和顺式作用终止区（CTS）的多核苷酸，这些区域是逆转录病毒或逆转录病毒样起源 所述载体另外包含定义的核苷酸序列（转基因或感兴趣的序列）以及逆转录病毒或逆转录病毒样起源的逆转录，表达和壳化的调控信号，其中所述组合物能够诱导或刺激细胞介导的应答 例如针对由载体中存在的转基因序列编码的一个或多个表位的CTL（细胞毒性T淋巴细胞）应答或CD4应答。

    Immunogenic Constructs
    64.
    发明申请
    Immunogenic Constructs 有权
    免疫原性构建体

    公开(公告)号：US20110129502A1

    公开(公告)日：2011-06-02

    申请号：US13007062

    申请日：2011-01-14

    申请人： John Hermon-Taylor ,  Timothy John Bull

    发明人： John Hermon-Taylor ,  Timothy John Bull

    IPC分类号： A61K39/04 ,  C07K14/00 ,  C07H21/04 ,  C12N15/63 ,  C12N5/10 ,  A61K31/7088 ,  A61P31/04

    CPC分类号： A61K39/04 ,  A61K39/00 ,  A61K2039/53 ,  A61K2039/541 ,  A61K2039/545 ,  C07K14/35 ,  C12N2799/022 ,  C12N2799/023 ,  Y10S435/975

    摘要： The present invention relates to molecules, which can be used to induce a therapeutic or prophylactic immune response against MAP. In particular, the present invention relates to polypeptides comprising an alipC polypeptide sequence, a gsd polypeptide sequence, a p12 polypeptide sequence and an mpa polypeptide sequence, wherein said ahpC polypeptide comprises the sequence of SEQ ID NO: 2, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 2 across the full length of SEQ ID NO: 2, or a fragment of at least 8 amino acids of SEQ ID NO: 2 which comprises an epitope; said gsd polypeptide comprises the sequence of SEQ ID NO: 6, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 6 across the full length of SEQ ID NO: 6, or a fragment of at least 8 amino acids of SEQ ID NO: 6 which comprises an epitope; said pi 2 polypeptide comprises the sequence of SEQ ID NO: 10, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 10 across the full length of SEQ ID NO: 10, or a fragment of at least 8 amino acids of SEQ ID NO: 10 which comprises an epitope; and said mpa polypeptide comprises the sequence of SEQ ID NO: 14, a variant thereof having more than 70% amino acid sequence identity to SEQ ID NO: 14 across the full length of SEQ ID NO: 14, or a fragment of at least 8 amino acids of SEQ ID NO: 14 which comprises an epitope. Preferably such a variant maintains the ability to generate an immune response against the unmodified polypeptide.

    摘要翻译： 本发明涉及可用于诱导针对MAP的治疗或预防性免疫应答的分子。 特别地，本发明涉及包含alipC多肽序列，gsd多肽序列，p12多肽序列和mpa多肽序列的多肽，其中所述ahpC多肽包含SEQ ID NO：2的序列，其变体具有多于 SEQ ID NO：2的全长与SEQ ID NO：2的70％氨基酸序列同一性，或包含SEQ ID NO：2的至少8个氨基酸的片段; 所述gsd多肽包含SEQ ID NO：6的序列，其在SEQ ID NO：6的全长上与SEQ ID NO：6具有超过70％的氨基酸序列同一性的变体，或至少8个氨基的片段 包含表位的SEQ ID NO：6的酸; 所述pi 2多肽包含SEQ ID NO：10的序列，其在SEQ ID NO：10全长与SEQ ID NO：10具有超过70％氨基酸序列同一性的变体，或至少8个 包含表位的SEQ ID NO：10的氨基酸; 并且所述mpa多肽包含SEQ ID NO：14的序列，其在SEQ ID NO：14全长与SEQ ID NO：14具有超过70％氨基酸序列同一性的变体，或至少8个 包含表位的SEQ ID NO：14的氨基酸。 优选地，这种变体保持产生针对未修饰多肽的免疫应答的能力。

    Mesothelin antibody protein fusions and methods of use
    65.
    发明授权
    Mesothelin antibody protein fusions and methods of use 有权
    间皮素抗体蛋白融合和使用方法

    公开(公告)号：US07943133B2

    公开(公告)日：2011-05-17

    申请号：US12291104

    申请日：2008-11-06

    申请人： Jeffrey A. Gelfand

    发明人： Jeffrey A. Gelfand

    IPC分类号： A61K39/00

    CPC分类号： C07K14/35 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/30 ,  C07K16/46 ,  C07K2319/00

    摘要： The invention relates to fusion proteins comprising a stress protein fused with an engineered antibody or fragment that binds to mesothelin, or a stress protein fused with a biotin-binding protein in combination with a biotinylated engineered antibody or fragment that binds to mesothelin. The invention also relates to fusion proteins comprising a stress protein fused with an antibody binding protein in combination with an engineered antibody or fragment that binds to mesothelin. The invention also relates to fusion proteins comprising an engineered antibody or fragment that binds specifically to mesothelin fused in frame with a biotin binding protein. The invention also provides fusion proteins comprising an engineered antibody or fragment, that binds to mesothelin, fused with an antibody binding protein. The invention also relates to methods of using fusion proteins of the invention to induce an immune response to mesothelin and to treat disease.

    摘要翻译： 本发明涉及包含与工程化抗体或与间皮素结合的片段融合的应激蛋白或与生物素结合蛋白融合的应激蛋白与融合了间皮素的生物素化工程化抗体或片段的融合蛋白。 本发明还涉及包含与抗体结合蛋白融合的应激蛋白与融合于间皮素的工程化抗体或片段组合的融合蛋白。 本发明还涉及包含与生物素结合蛋白框架融合的间皮素的特异性结合的工程化抗体或片段的融合蛋白。 本发明还提供融合蛋白，其包含与抗体结合蛋白融合的间皮素的工程化抗体或片段。 本发明还涉及使用本发明的融合蛋白诱导对间皮素的免疫应答并治疗疾病的方法。

    Specific epitope based immunological diagnosis of tuberculosis
    69.
    发明授权
    Specific epitope based immunological diagnosis of tuberculosis 有权
    特异性表位基因免疫诊断结核病

    公开(公告)号：US07838013B2

    公开(公告)日：2010-11-23

    申请号：US11268959

    申请日：2005-11-08

    申请人： Peter Andersen ,  Inger Brock ,  Karin Weldingh

    发明人： Peter Andersen ,  Inger Brock ,  Karin Weldingh

    IPC分类号： A61K39/04 ,  A61K39/00 ,  C12Q1/00

    CPC分类号： G01N33/6812 ,  C07K14/35 ,  G01N33/505 ,  G01N33/5695

    摘要： The currently used method for immunological diagnosis of tuberculosis infection, the tuberculin skin test, is problematic for a number of reasons; it has low specificity in BCG vaccinated individuals, a high interobserver variance and requires skill to be read and interpreted. Furthermore it requires an extra visit to the clinic to have the test read. Both people vaccinated with BCG and those exposed to non-tuberculosis mycobacteria give a positive skin test result similar to that seen in a TB infected individual. This also applies for purified protein derivative (PPD) when used in a blood cell based test. The present invention discloses the development of an immunological TB diagnostic tool based on a combination of epitopes from proteins encoded by regions of the M. tuberculosis (M. tub.) genome, that are not present in the BCG vaccine strain or in the most common non-tuberculosis mycobacteria.

    摘要翻译： 目前使用的结核菌感染免疫诊断方法，结核菌素皮肤试验，有其原因有问题; 它在BCG接种个体中具有低特异性，具有高的观察者间差异，并且需要阅读和解释技能。 此外，还需要额外访问诊所以进行测试。 接种BCG的人和暴露于非结核分枝杆菌的两个人都能获得与TB感染个体相似的阳性皮肤试验结果。 当用于基于血细胞的试验中时，这也适用于纯化的蛋白质衍生物（PPD）。 本发明公开了一种免疫结核病诊断工具的开发，该工具基于由结核分枝杆菌（M.Bob。）基因组区域编码的蛋白质的表位的组合，其不存在于BCG疫苗株中或最常见 非结核分枝杆菌。